President & CEO
Mr. Ganske brings over 3 decades of both public and private company experience in the medical devices, diagnostics, and life science fields, and has a broad background in management, operations, science and regulatory; blended with the disciplines of corporate processes, and successful entrepreneurial business ventures. Mr. Ganske has personally led multiple business and IP transactions with both Fortune 100 and Fortune 500 companies. He led CellAegis Devices Inc. as the CEO for the last 10 years transitioned the technology out of Sick Kids Hospital, Toronto into a commercial product with CE Mark and Health Canada approval used in several multinational controlled trials, in cardiovascular, stroke, and kidney reperfusion damage.
Prior to CDI, Mr. Ganske served as CEO of Axela, a university diagnostics startup focused on real-time proteomic analysis utilizing proprietary diffractive optics technology. Mr. Ganske transitioned Axela to a full operating company, installing Axela’s commercial platform in premier institutes in the US, EU and Asia Pacific. Mr. Ganske was instrumental in negotiating and closing significant patent in-licensing transaction with Fortune 100 companies for over 150 patents and applications and oversaw Axela’s acquisition of Xceed Molecular, a genomics diagnostic company.
Dr. John Mackey, MD.
Chief Medical Officer
Dr. Mackey, is a medical oncologist and Director of the Clinical Trials Unit at the Cross Cancer Institute in Edmonton, Canada, and a Professor of Oncology at the University of Alberta. In addition to acting as director and lead clinical advisor to illumiSonics, Dr Mackey brings deep medtech commercialization experience. He co-founded Pacylex Pharmaceuticals, J2 Endeavours, and SMHeartCard Inc. As Chair of the Alberta Pre-Phase I Program steering committee, he has a highly skilled team committed to bringing new anticancer therapies into clinical testing (www.prephaseone.com). Dr. Mackey has authored or co-authored more than 300 biomedical peer reviewed publications.
Dr. Parsin Haji Reza, PhD.
Founder & CTO
Dr. Reza discovered and pioneered the PARS™ imaging techniques. In November 2014, he co-founded illumiSonics inc., holding the position of CEO from November 2014 to March 2018. Dr. Reza is an award winning Assistant Professor at the University of Waterloo and leads a team of optical imaging experts at PhotoMedicine Labs. He brings more than 10 years experience in optics and biomedical engineering, and continues to advance the validation of PARS™ through these efforts and currently has 35+ peer reviewed journal papers in optics and biomedical Engineering. He has been recognized for his innovative scientific contributions to advancing the state of optical imaging.